TRDA NASDAQ
Credit Risk of going bust: higher than 88% of companies Debt: 20.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.24 (down 95%), Entrada Therapeutics, Inc. would be worth roughly what it owes.
Total debt $48.5M against a stock market value of $184.9M.
Distance to default 1.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $24.3M (short-term plus half of long-term), stock volatility 107.8%; Altman Z'' 0.79. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Boston, MA 02210
US
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| MPM BIOVENTURES 2018 | S-Sale | 28,837 | $7.13 | 2026-09-09 |
| MPM BioVentures 2014 | S-Sale | 28,837 | $7.13 | 2026-09-09 |
| MPM BIOVENTURES 2018 | S-Sale | 192,500 | $7.41 | 2026-09-08 |
| MPM BioVentures 2014 | S-Sale | 192,500 | $7.41 | 2026-09-08 |
| MPM BIOVENTURES 2018 | S-Sale | 38,500 | $7.11 | 2026-09-04 |